Search This Blog

Wednesday, October 12, 2022

Moderna exercises option to license targeting technology from Autolus

 Option exercised on undisclosed immune-oncology target following evaluation period by Moderna -

- Autolus receives option exercise fee, with potential for development milestone payments plus royalties -

https://finance.yahoo.com/news/moderna-exercises-option-license-proprietary-110000823.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.